Revenue and Profit - Revenue for Q3 2025 was $19,462 thousand, a 22% increase from $15,853 thousand in Q3 2024[5] - Gross profit for Q3 2025 reached $12,907 thousand, up from $10,654 thousand in Q3 2024, reflecting a 21% growth[5] - The revenue from the SOPHiA DDM Platform for the three months ended September 30, 2025, was $18.667 million, up from $15.584 million in 2024, representing a growth of 19%[45] Losses and Financial Position - Operating loss for the nine months ended September 30, 2025, was $52,390 thousand, compared to $49,124 thousand for the same period in 2024, indicating a 5% increase in losses[5] - Total comprehensive loss for Q3 2025 was $20,235 thousand, compared to $11,621 thousand in Q3 2024, representing a 74% increase in losses[7] - The accumulated deficit as of September 30, 2025, was $500,097 thousand, up from $440,277 thousand at the end of 2024, indicating a worsening financial position[10] - For the nine months ended September 30, 2025, the loss before tax was $57,913 thousand, compared to a loss of $46,728 thousand for the same period in 2024[13] - The net loss attributed to shareholders for the three months ended September 30, 2025, was $20.021 million, compared to a loss of $18.438 million in 2024[47] Cash and Liquidity - Cash and cash equivalents as of September 30, 2025, were $81,610 thousand, slightly up from $80,226 thousand at the end of 2024[9] - Cash used in operating activities for the nine months ended September 30, 2025, was $27,757 thousand, a decrease from $33,829 thousand in the prior year[13] - The net cash flow provided by financing activities for the nine months ended September 30, 2025, was $30,562 thousand, compared to $11,025 thousand in 2024[13] - As of September 30, 2025, cash and cash equivalents were $81,610 thousand, down from $95,787 thousand at the end of the previous year[13] Assets and Liabilities - Total assets increased to $163,458 thousand as of September 30, 2025, from $155,309 thousand at the end of 2024, marking a 5% growth[9] - Total liabilities rose to $102,771 thousand as of September 30, 2025, compared to $58,819 thousand at the end of 2024, reflecting a significant increase of 74%[9] Expenses - Research and development costs for Q3 2025 were $8,067 thousand, slightly higher than $7,874 thousand in Q3 2024[5] - Selling and marketing costs increased to $8,670 thousand in Q3 2025 from $7,306 thousand in Q3 2024, a rise of 18.7%[5] - The company reported share-based compensation of $12,337 thousand for the nine months ended September 30, 2025, compared to $11,410 thousand in the prior year[13] - The total interest expense recorded for the nine months ended September 30, 2025, was $2.486 million[60] - The Company reported share-based compensation expenses totaling $4.146 million for the three months ended September 30, 2025, compared to $3.613 million for the same period in 2024[62] Financing Activities - The Company drew down $35.0 million from the second tranche of term loans on June 25, 2025, under the Perceptive Credit Agreement[51] - The Company accounted for Tranche B of the term loans and warrants as two separate financial instruments, with a total drawdown of $35.0 million[52] - The Tranche A loan was recorded at an initial amortized cost of $13.3 million, while Tranche B was recorded at an initial amortized cost of $34.1 million[59] - The effective interest rate (EIR) for Tranche B was determined to be 12.4% upon initial drawdown[56] - The fair value of the Tranche A warrant obligation was initially measured at $0.7 million, and for Tranche B at $0.5 million[57] - As of September 30, 2025, the Company had no borrowings outstanding under the new credit facility with Credit Suisse SA[61] Other Financial Information - The Company signed a stock purchase agreement to acquire a minority equity interest in A.D.A.M. Innovations for a total of $2.0 million, with $0.5 million acquired in September 2025 and $1.5 million in October 2025[41] - The Company completed its purchase of shares in A.D.A.M. Innovations for $1.5 million in October 2025[66] - The Company entered into a 73-month lease for office space in Boston, Massachusetts, with a right-of-use asset recorded at $2.0 million[48] - The Company’s accounts receivable as of September 30, 2025, amounted to $8.455 million, an increase from $7.436 million as of December 31, 2024[46] - The allowance for expected credit losses decreased to $345,000 as of September 30, 2025, from $394,000 as of December 31, 2024[46] - The Company’s largest customer represented 9% of accounts receivable as of September 30, 2025, down from 18% as of December 31, 2024[46] - Key management personnel compensation for the nine months ended September 30, 2025, totaled $11.103 million, compared to $13.788 million for the same period in 2024[65] Accounting Changes - The company reclassified interest paid from operating activities to financing activities, and interest received from operating activities to investing activities effective January 1, 2025[24] - The company is currently evaluating the impact of IFRS 18, effective January 1, 2027, on its financial statements[30]

Core Insights - A.D.A.M. Innovations and SOPHiA GENETICS have formed a strategic partnership to introduce advanced liquid biopsy genomic testing in Japan, aiming to enhance personalized cancer care [1][4][5] - The collaboration will leverage SOPHiA's AI-powered DDM Platform to improve cancer testing efficiency and accuracy, with a focus on local testing and research [2][3][5] Company Overview - A.D.A.M. Innovations has been a leader in genetic testing in Japan for over 20 years, having conducted more than 2.8 million genomic tests [2][9] - SOPHiA GENETICS is a cloud-native healthcare technology company specializing in AI-driven data analysis for cancer and rare disorders [6] Partnership Details - The initial focus will be on launching the MSK-ACCESS® liquid biopsy application, which detects genomic alterations from a single blood draw using AI to analyze circulating tumor DNA [3][4] - The companies plan to develop a liquid biopsy companion diagnostic test to enhance access to tumor profiling and support drug development in Japan [4][5] Strategic Goals - The partnership aims to make precision oncology more accessible in Japan, combining local expertise with global technology to drive the adoption of data-driven medicine [5] - A.D.A.M. Innovations will utilize its clinical and regulatory knowledge to facilitate the development and approval processes for new diagnostic tools [4][5]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - rYojbaba Co., Ltd. (RYOJ) increased by 134% to $5.09 - Linkage Global Inc (LGCB) rose by 101% to $3.33 - MIRA Pharmaceuticals, Inc. (MIRA) gained 87% to $2.46 - Auddia Inc. (AUUD) went up by 23% to $2.54 - SOPHiA GENETICS SA (SOPH) increased by 16% to $4.99 - J.B. Hunt Transport Services, Inc. (JBHT) rose by 13% to $157.44 - AlphaVest Acquisition Corp (ATMV) increased by 11% to $13.09 - New Era Energy & Digital, Inc. (NUAI) went up by 10% to $3.71 - Critical Metals Corp. (CRML) rose by 9% to $24.80 - Blaize Holdings, Inc. (BZAI) increased by 9% to $6.90 [3] Premarket Losers - Fossil Group, Inc. (FOSL) decreased by 40% to $2.23 - Pinnacle Food Group Limited (PFAI) fell by 25% to $3.41 - American Battery Technology Company (ABAT) declined by 22% to $6.91 - Sadot Group Inc. (SDOT) dropped by 20% to $6.15 - TechCreate Group Ltd. (TCGL) decreased by 14% to $4.14 - PMGC Holdings Inc. (ELAB) fell by 13% to $6.43 - Arcadia Biosciences, Inc. (RKDA) decreased by 13% to $4.73 - ATIF Holdings Limited (ZBAI) dropped by 11% to $9.28 - Roma Green Finance Limited (ROMA) fell by 7% to $2.62 - Australian Oilseeds Holdings Limited (COOT) decreased by 6% to $2.46 [4]

Core Insights - SOPHiA GENETICS has launched SOPHiA DDM™ Digital Twins, a technology that creates virtual representations of individual patients to aid oncologists in treatment decision-making [1][7] - The Digital Twins utilize a patient's unique clinical, biological, imaging, and genomic data to simulate treatment responses and disease trajectories in real time [1][4] - This technology aims to enhance personalized treatment insights, reduce unnecessary side effects and costs, and leverage a global dataset for improved clinical decisions [6][7] Technology Overview - SOPHiA DDM™ Digital Twins enables integrative visualization of multimodal oncologic data, revealing correlations across different data types [2] - The technology supports in silico experimentation, allowing for anticipatory and individualized clinical decision-making [2][4] - It continuously evolves with new data, improving accuracy and research capabilities over time [5][6] Clinical Implications - The Digital Twins concept is seen as transformative for oncology, particularly in managing complex cancers and pre-surgical immunotherapy for non-small cell lung cancer [3][5] - Clinicians can simulate potential outcomes before treatment, which may significantly change future care delivery [3][4] - The tool provides insights derived from a broad network of global patient cases, breaking down institutional and geographic barriers [3][6] Future Directions - The launch of Digital Twins marks a shift towards AI-powered decision support in precision oncology, moving beyond retrospective evidence [7] - Initially available for lung cancer, the technology will expand to include more cancer types in the coming months [7] - SOPHiA GENETICS aims to make data-driven medicine the global standard of care through this innovative approach [6]

Core Insights - Biotech stocks experienced a significant after-hours rally, with SOPHiA GENETICS and SELLAS Life Sciences leading the gains due to positive announcements regarding upcoming data presentations [1][2]. Company Highlights - SOPHiA GENETICS (SOPH) saw its shares increase by nearly 10%, closing at $4.44 [3]. - SELLAS Life Sciences Group Inc. (SLS) shares rose by 3.5% to $2.07 after announcing the presentation of preclinical efficacy data for its CDK9 inhibitor, SLS009, at the ESMO Congress 2025 [2]. - Other notable biotech companies that experienced stock price increases include Ironwood Pharmaceuticals (up 6.76% at $1.58), Spectral AI (up 8.60% at $2.40), and Adverum Biotechnologies (up 7.21% at $4.46) [3].

Core Insights - Two health-tech stocks are experiencing a significant surge in their Momentum scores, indicating strong performance relative to other stocks [1][2] Group 1: Sophia Genetics SA - Sophia Genetics SA's Momentum score increased from 32.45 to 81.80 over the past week [3] - The stock has surged by 30% in the past month due to an expanded collaboration with AstraZeneca PLC to develop an AI-powered next-generation sequencing solution for breast and prostate cancer [4] - The stock shows a favorable price trend across short, medium, and long-term time frames [4] Group 2: DarioHealth Corp - DarioHealth Corp's Momentum score rose from 7.69 to 59.45 within a week [5] - The stock has increased by over 83% in the past month, driven by the announcement of a committee exploring a potential sale, merger, or business combination [5] - Similar to Sophia Genetics, DarioHealth Corp also exhibits a favorable price trend in the short, medium, and long terms [6]

Core Insights - Myriad Genetics and SOPHiA GENETICS have announced a strategic collaboration to develop a global liquid biopsy companion diagnostic test for pharmaceutical companies [1] Company Overview - Myriad Genetics is recognized as a leader in molecular diagnostic testing and precision medicine [1] - SOPHiA GENETICS is an AI technology company focused on transforming precision medicine [1] Collaboration Details - The collaboration aims to innovate and provide pharmaceutical companies with advanced diagnostic solutions [1]

Core Insights - Myriad Genetics and SOPHiA GENETICS have announced a strategic collaboration to develop a global liquid biopsy companion diagnostic test for pharmaceutical companies, leveraging Myriad's laboratory capabilities and SOPHiA's extensive network [1][2][3] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being through molecular tests that guide treatment decisions [9] - SOPHiA GENETICS is a cloud-native healthcare technology company that utilizes AI to enhance access to data-driven medicine, particularly in oncology and rare disorders [5] Collaboration Details - The partnership will initially focus on the MSK-ACCESS® liquid biopsy application, which detects genomic alterations from a single blood draw using advanced algorithms [2] - Myriad will handle regulatory submissions in the U.S., while SOPHiA will manage submissions outside the U.S., aiming to provide access to key regulated markets globally [3] Industry Impact - This collaboration is seen as a pivotal moment for the industry, combining the strengths of a specialty lab and a global testing network to expand access to innovative oncology testing [4] - The hybrid model in companion diagnostics is expected to enhance service to both clinical and pharmaceutical partners, accelerating the adoption of liquid biopsy solutions [4]

Core Insights - SOPHiA GENETICS expands collaboration with AstraZeneca to enhance diagnosis and treatment of breast and prostate cancer through an optimized next generation sequencing (NGS) solution utilizing AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway [1][5] Group 1: Collaboration Details - The partnership aims to improve the detection of genetic mutations linked to cancer development, particularly focusing on the PTEN gene, which when altered, can lead to cancer and treatment resistance [2] - An optimized NGS solution has been developed that employs AI agents to analyze and detect genomic mutations across the full PTEN gene, with a prototype showing improved sensitivity for complex mutations [2][3] Group 2: Implementation and Future Plans - SOPHiA GENETICS will initiate a Privileged Access Program for selected clinical laboratories to validate the sensitivity of the NGS solution in real-world settings, with broader commercial availability anticipated in 2026 [3] - A multi-center real-world evidence study will be conducted to further assess the effectiveness of the solution, aiming to expand patient access to precision therapies through advanced testing in both tissue and liquid biopsy [3] Group 3: Company Mission and Vision - The collaboration reflects the commitment of both companies to drive innovation in precision oncology, ensuring global patient access to advanced genomic testing and targeted treatments [5] - SOPHiA GENETICS emphasizes its mission to democratize data-driven medicine, translating new cancer insights into actionable solutions for patients worldwide [4]

Core Insights - SOPHiA GENETICS has announced a collaboration with Jessa Ziekenhuis to enhance genomic testing and oncology research for cancer patients in Belgium [1][8] - The partnership aims to unify next-generation sequencing (NGS) workflows under a single platform, improving efficiency and compliance with national guidelines [2][5] Group 1: Collaboration Details - Jessa Ziekenhuis processes over 3,000 oncology DNA and RNA samples annually and will implement SOPHiA DDM™ across its pathology operations [2] - The collaboration will involve six SOPHiA GENETICS applications tailored for solid tumors, hematologic malignancies, and liquid biopsy analysis [3] - The integration of SOPHiA GENETICS' cloud-based platform with Jessa Ziekenhuis's Laboratory Information Management System (LIMS) will streamline operations [4] Group 2: Expected Benefits - Jessa Ziekenhuis anticipates a reduction in hands-on time by 30-50% and overall costs by up to 25% through the unified NGS operation [5] - The collaboration will enhance testing turnaround times and improve the scalability of sequencing services [5][6] - The SOPHiA DDM™ Dispatch feature will allow Jessa Ziekenhuis to share a NovaSeq sequencer with AZ Delta, optimizing sequencing capacity and knowledge sharing [6] Group 3: Strategic Importance - The partnership exemplifies SOPHiA GENETICS' commitment to supporting healthcare institutions in scaling genomics capabilities while ensuring quality and efficiency [8] - This collaboration strengthens SOPHiA GENETICS' presence in European hospital networks, promoting data-driven precision medicine [8][9]